Masashi Namikawa

Expression of amino acid transporters (<scp>LAT1</scp>, <scp>ASCT2</scp> and <scp>xCT</scp>) as clinical significance in hepatocellular carcinoma

Masashi Namikawa, Satoru Kakizaki, Kyoichi Kaira et al. · Hepatology Research · 2014 · 60 citations

Analyses of objective response rate, progression‐free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study

Takeshi Hatanaka, Satoru Kakizaki, Tamon Nagashima et al. · Hepatology Research · 2019 · 36 citations

The Role of the Albumin-Bilirubin Score for Predicting the Outcomes in Japanese Patients with Advanced Hepatocellular Carcinoma Treated with Ramucirumab: A Real-World Study

Takeshi Hatanaka, Atsushi Naganuma, Mitsuhiko Shibasaki et al. · Oncology · 2020 · 24 citations

Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Yoshinari Takaoka, Kouichi Miura, Naoki Morimoto et al. · Hepatology Research · 2020 · 23 citations

Optimal follow‐up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated‐interferon and ribavirin

Masashi Namikawa, Satoru Kakizaki, Yutaka Yata et al. · Journal of Gastroenterology and Hepatology · 2011 · 21 citations